Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Fundamental Analysis

NASDAQ:CYCN - Nasdaq - US23255M2044 - Common Stock

2.91  +0.01 (+0.34%)

Fundamental Rating

2

Taking everything into account, CYCN scores 2 out of 10 in our fundamental rating. CYCN was compared to 572 industry peers in the Biotechnology industry. The financial health of CYCN is average, but there are quite some concerns on its profitability. CYCN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYCN had negative earnings in the past year.
CYCN had a negative operating cash flow in the past year.
In the past 5 years CYCN always reported negative net income.
In the past 5 years CYCN always reported negative operating cash flow.
CYCN Yearly Net Income VS EBIT VS OCF VS FCFCYCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -59.15%, CYCN perfoms like the industry average, outperforming 40.88% of the companies in the same industry.
CYCN has a Return On Equity (-64.20%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.15%
ROE -64.2%
ROIC N/A
ROA(3y)-123.33%
ROA(5y)-100.67%
ROE(3y)-191.2%
ROE(5y)-166.05%
ROIC(3y)N/A
ROIC(5y)N/A
CYCN Yearly ROA, ROE, ROICCYCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K -1.5K

1.3 Margins

CYCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCN Yearly Profit, Operating, Gross MarginsCYCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

CYCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYCN has more shares outstanding
CYCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCN Yearly Shares OutstandingCYCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
CYCN Yearly Total Debt VS Total AssetsCYCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -38.63, we must say that CYCN is in the distress zone and has some risk of bankruptcy.
CYCN's Altman-Z score of -38.63 is on the low side compared to the rest of the industry. CYCN is outperformed by 92.92% of its industry peers.
There is no outstanding debt for CYCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.63
ROIC/WACCN/A
WACC11.11%
CYCN Yearly LT Debt VS Equity VS FCFCYCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 5.07 indicates that CYCN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.07, CYCN is in line with its industry, outperforming 54.16% of the companies in the same industry.
A Quick Ratio of 5.07 indicates that CYCN has no problem at all paying its short term obligations.
The Quick ratio of CYCN (5.07) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.07
Quick Ratio 5.07
CYCN Yearly Current Assets VS Current LiabilitesCYCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.92% over the past year.
CYCN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)88.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.23%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYCN Yearly Revenue VS EstimatesCYCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
CYCN Yearly EPS VS EstimatesCYCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCN Price Earnings VS Forward Price EarningsCYCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCN Per share dataCYCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYCN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (1/22/2025, 2:47:06 PM)

2.91

+0.01 (+0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)03-03 2025-03-03
Inst Owners40.09%
Inst Owner Change0%
Ins Owners23.53%
Ins Owner Change0%
Market Cap7.89M
Analysts82.86
Price TargetN/A
Short Float %4.1%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0
BVpS3.03
TBVpS3.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.15%
ROE -64.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.33%
ROA(5y)-100.67%
ROE(3y)-191.2%
ROE(5y)-166.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.07
Quick Ratio 5.07
Altman-Z -38.63
F-Score3
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y78.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.22%
OCF growth 3YN/A
OCF growth 5YN/A